News from ajmc.comFollowNews from ajmc.comSee all of ajmc.com news coverage in one place. Discover how ajmc.com’s media bias informs their coverage and compare with thousands of other news outlets.We’ve aggregated 583 of ajmc.com’s headlines and news stories over the past 3 months. ajmc.com’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. ajmc.com’s aggregated factuality score is unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.Follow See all of ajmc.com news coverage in one place. Discover how ajmc.com’s media bias informs their coverage and compare with thousands of other news outlets. We’ve aggregated 583 of ajmc.com’s headlines and news stories over the past 3 months. ajmc.com’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. ajmc.com’s aggregated factuality score is unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check. Information about ajmc.comWhere is ajmc.com located?ajmc.com's WebsiteMedia Bias RatingsDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: UnknownLearn more about Factuality Ratings.Top ajmc.com NewsCancerBreakthrough discovery of selective MMP7 inhibitor offers hope for cancer treatmentCoverage: 2 sourcesA team of researchers from the Hebrew University of Jerusalem, the Weizmann Institute of Science, and the University of Tokyo has made a significant breakthrough in the fight against cancer by developing a highly selective inhibitor for an enzyme called Matrix Metallopeptidase 7 (MMP7).See the StoryBreast Cancer · United StatesPI3K Inhibitor Wins FDA Approval for Advanced Breast Cancer100% Center coverage: 1 sourcesThe FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and fulvestrant to treat locally advanced, PIK3CA-mutated, hormone receptor (HR)-positive/HER2-negative breast cancer that recurred during or after adjuvant endocrine therapy. Support for the approval came from the multicenter randomized INAVO120 trial, which showed that the addition of inavolisib to palbociclib […]See the StoryFDA · United StatesFDA Approves Optune Lua Device in NSCLCOptune Lua creates tumor-treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 inhibitors or docetaxel to treat metastatic non–small cell lung cancer (NSCLC) that has not responded to platinum-based treatment.See the StoryLatest News StoriesTopics Most Covered by ajmc.comCancerArtificial IntelligenceHealthHealth CareHIVCancerArtificial IntelligenceHealthSources Covering Similar TopicsMedPage TodayPharmacy Timesonclive.comThe Hillhcplive.comMedPage TodayPharmacy Timesonclive.comSuggest a sourceLooking for a source we don't already have? Suggest one here.You've scrolled to the bottom of the feed, there are no more stories.Breaking News Topics Related to ajmc.comCalifornia, United StatesMarylandHealthHealth CareMassachusettsCancerArtificial IntelligenceUnited States